No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
388 |
4. Check minimum number of eventsNone |
388 |
5. Include endpointsNone |
388 |
6. Filter based on genotype QC (FinnGen only) |
363 |
Control definitions (FinnGen only)
- Control exclude
- G6_DEMYEL
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- G35-G37
- Name in latin
- Alia demyelinatio disseminata acuta
Similar endpoints
↥List of similar endpoints to
Other acute disseminated demyelination
based on the number of shared cases.
Similar with more cases:
- Demyelinating diseases of the central nervous system
- Autoimmune diseases
- Used for control exclusion in common control thyroid runs
- Neurological diseases
- Neurological diseases, wide definition
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2214 | 1475 | 720 |
| Only index persons | 2052 | 1408 | 644 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.04 | 0.02 |
| Only index persons | 0.04 | 0.05 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 38.77 | 38.00 | 40.00 |
| Only index persons | 37.80 | 37.69 | 38.05 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 363 | 271 | 92 |
| Unadjusted period prevalence (%) | 0.08 | 0.10 | 0.04 |
| Median age at first event (years) | 38.30 | 37.31 | 41.22 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 388
- Matched controls
- 3880
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G35
ICD-10 Finland
Multiple sclerosis
3948.9
316.8
262
*
G36.9
ICD-10 Finland
Acute disseminated demyelination, unspecified
+∞
307.7
264
*
109
Kela drug reimbursment
Multiple sclerosis
+∞
239.1
204
*
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
+∞
227.1
195
*
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
+∞
211.4
183
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
21.1
198.2
190
169
TAB00
NOMESCO Finland
Lumbar puncture
21.0
153.5
132
93
L03AB07
ATC
interferon beta-1a; parenteral
+∞
128.5
116
*
H46
ICD-10 Finland
Optic neuritis
203.3
115.5
115
8
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
+∞
110.9
101
*
N04BB01
ATC
amantadine; oral
65.6
109.5
61
11
G36.0
ICD-10 Finland
Neuromyelitis optica [Devic]
+∞
105.1
96
*
L03AX13
ATC
glatiramer acetate; parenteral
+∞
101.6
93
*
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
9.4
87.0
128
193
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
25.6
81.5
59
27
N86
ICPC
Multiple sclerosis
893.2
77.1
73
*
XCK00
NOMESCO Finland
Perimetry
12.6
72.7
78
76
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
33.8
69.1
45
15
XA800
NOMESCO Finland
Neuropsychological investigation
11.5
67.4
77
82
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
16.8
67.0
59
41
164
Kela drug reimbursment
Fingolimod
+∞
66.6
62
*
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
23.7
64.7
48
23
ZX120
NOMESCO Finland
Intravenous
7.5
57.7
97
165
353
Kela drug reimbursment
Cladribine and fingolimod
+∞
56.7
53
*
M03BX01
ATC
baclofen; systemic
18.7
54.8
45
27
L04AA31
ATC
[U] teriflunomide
+∞
54.5
51
*
L04AA27
ATC
[U] fingolimod
+∞
52.3
49
*
N07XX09
ATC
[U] dimethyl fumarate
+∞
51.2
48
*
L04AX07
ATC
dimethyl fumarate; oral
+∞
51.2
48
*
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
8.7
49.6
69
94
L03AB08
ATC
interferon beta-1b; parenteral
+∞
47.9
45
*
Z01.0
ICD-10 Finland
Examination of eyes and vision
4.6
41.7
130
380
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
6.0
41.6
85
173
R20.2
ICD-10 Finland
Paraesthesia of skin
5.8
40.0
84
175
XKD06
NOMESCO Finland
Physiologic investigation of micturition
14.5
39.6
37
28
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
12.3
37.7
39
35
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
7.7
37.1
56
83
XCD10
NOMESCO Finland
Electrophysiological examination of eye
14.1
37.0
35
27
H53.2
ICD-10 Finland
Diplopia
11.1
36.9
41
41
2AB04, ,
NOMESCO Finland
203.9
36.4
37
*
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
14.4
34.4
32
24
XKC03
NOMESCO Finland
Water cystometry
11.0
34.1
38
38
G04BD12
ATC
mirabegron; oral
6.0
33.4
66
129
UKC02
NOMESCO Finland
Cystoscopy
4.8
30.0
79
198
G04BD08
ATC
solifenacin; oral
7.5
27.7
42
62
G36.8
ICD-10 Finland
Other specified acute disseminated demyelination
+∞
27.4
26
*
L04AK02
ATC
teriflunomide; oral
+∞
26.3
25
*
H02AB04
ATC
methylprednisolone; systemic
3.8
26.1
96
307
N03AX12
ATC
[U] gabapentin; oral
3.6
25.7
105
360
F02.89*G35
ICD-10 Finland
Dementia in multiple sclerosis
+∞
22.1
21
*
N03AE01
ATC
clonazepam; systemic
5.5
21.5
44
88
L03AB13
ATC
peginterferon beta-1a; parenteral
+∞
21.0
20
*
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
32.1
20.8
27
9
XKD00
NOMESCO Finland
Uroflowmetry
4.4
20.8
57
146
L04AE01
ATC
fingolimod; oral
+∞
20.0
19
*
XCW99
NOMESCO Finland
Other investigative procedure of eye
4.3
19.7
56
147
N06BA07
ATC
modafinil; oral
48.7
19.4
23
5
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
20.0
18.9
28
15
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
4.5
18.1
47
115
4AA23, ,
NOMESCO Finland
+∞
17.8
17
*
G04.9
ICD-10 Finland
Encephalitis, myelitis and encephalomyelitis, unspecified
+∞
17.8
17
*
R1250
NOMESCO Finland
Evaluation of functional capability
6.9
16.4
26
40
L04AX01
ATC
azathioprine; systemic
5.1
16.2
36
77
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
6.5
16.1
27
44
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
4.1
16.0
47
126
G04BD09
ATC
trospium; oral
16.6
15.9
25
16
Z2445
NOMESCO Finland
Psychologist
4.5
15.2
39
94
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
3.9
15.2
47
131
TKC22
NOMESCO Finland
Catheterisation instruction
20.1
14.4
21
11
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
44.3
14.2
17
*
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
13.4
14.1
24
19
N31.9
ICD-10 Finland
Neuromuscular dysfunction of bladder, unspecified
24.9
13.9
19
8
Z01.8
ICD-10 Finland
Other specified special examinations
2.5
13.7
110
530
G37.3
ICD-10 Finland
Acute transverse myelitis in demyelinating disease of central nervous system
+∞
13.6
13
*
O99.3
ICD-10 Finland
Mental disorders and diseases of the nervous system complicating pregnancy, childbirth and the puerperium
5.6
13.4
26
49
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.2
13.1
169
996
N28
ICPC
Limited function/disability (N)
20.9
12.6
18
9
L04AA40
ATC
cladribine; oral
+∞
12.6
12
*
G36.1
ICD-10 Finland
Acute and subacute haemorrhagic leukoencephalitis [Hurst]
+∞
12.6
12
*
L04AG12
ATC
ofatumumab; parenteral
+∞
12.6
12
*
N05CF01
ATC
zopiclone; oral
2.3
12.5
138
760
R35
ICD-10 Finland
Polyuria
4.1
12.2
35
92
XKD03
NOMESCO Finland
Urethral pressure profilometry
10.6
12.2
23
23
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
4.5
12.0
30
71
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.0
11.9
59
221
A02BC02
ATC
pantoprazole; systemic
2.2
11.9
270
1962
L28
ICPC
Limited function/disability (L)
2.8
11.8
64
252
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
2.7
11.6
69
285
WW400
NOMESCO Finland
Plasmaferesis
+∞
11.5
11
*
N39.4
ICD-10 Finland
Other specified urinary incontinence
3.6
11.4
40
121
N03AX16
ATC
[U] pregabalin
2.3
11.4
106
541
N99
ICPC
Neurological disease other
17.7
11.3
17
10
A28
ICPC
Limited function/disability NOS
3.1
11.3
52
187
G95.8
ICD-10 Finland
Other specified diseases of spinal cord
44.7
11.0
13
*
N06AX21
ATC
duloxetine; oral
2.6
10.8
72
315
J01EA01
ATC
trimethoprim; systemic
2.2
10.5
121
671
XCK10
NOMESCO Finland
Photography of fundus of eye
3.2
10.5
43
144
H48.1*G35
ICD-10 Finland
Retrobulbar neuritis in multiple sclerosis
+∞
10.5
10
*
H57.1
ICD-10 Finland
Ocular pain
3.9
10.4
31
84
KCV12
NOMESCO Finland
Urinary bladder endoscopic botulin therapy
24.1
10.3
14
6
Z3226
NOMESCO Finland
Physiotherapist
2.4
10.1
83
399
R4150
NOMESCO Finland
Neuropsychological rehabilitation
11.0
9.9
18
17
AA1AD
NOMESCO Finland
CT of head and brain
2.3
9.8
93
476
G04BD07
ATC
tolterodine; oral
4.4
9.5
24
57
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
3.1
9.3
40
138
R42
ICD-10 Finland
Dizziness and giddiness
2.3
9.2
84
421
G04BD11
ATC
fesoterodine; oral
8.6
9.2
19
23
R90.8
ICD-10 Finland
Other abnormal findings on diagnostic imaging of central nervous system
9.4
9.1
18
20
SPAT1229
SPAT
Assessment of need for aid
4.0
9.1
26
68
SPAT1216
SPAT
Assessment of functional ability
2.7
8.9
53
218
R4120
NOMESCO Finland
Occupational therapy
3.1
8.8
37
126
R5110, ,
SPAT
3.9
8.5
25
67
H53.4
ICD-10 Finland
Visual field defects
8.1
8.5
18
23
N32.83
ICD-10 Finland
Nozzle synergy in the bladder neck
92.0
8.4
9
*
H51.2
ICD-10 Finland
Internuclear ophthalmoplegia
+∞
8.4
8
*
N29
ICPC
Neurological sympt/complt other
9.8
8.4
16
17
CS494
NOMESCO Finland
Other visual field testing
7.8
8.3
18
24
A02BA02
ATC
ranitidine; systemic
2.3
7.8
68
333
R33
ICD-10 Finland
Retention of urine
3.7
7.8
25
71
U13
ICPC
Bladder symptom/complaint other
6.4
7.6
19
31
N02BF01
ATC
gabapentin; oral
2.7
7.6
42
166
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
3.6
7.5
25
73
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.3
7.3
58
273
L04AA52
ATC
[U] ofatumumab; parenteral
+∞
7.3
7
*
CA1CG
NOMESCO Finland
Eye and orbita extensive MRI examination with high intensity magnet
16.1
7.3
11
7
G04BD04
ATC
oxybutynin; oral, transdermal
3.6
7.2
24
70
H53.1
ICD-10 Finland
Subjective visual disturbances
2.8
7.2
36
135
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
3.5
6.9
24
72
U04
ICPC
Incontinence urine
3.9
6.9
20
53
G51.0
ICD-10 Finland
Bell palsy
4.4
6.8
17
40
G04CA02
ATC
tamsulosin; oral
2.4
6.8
49
221
H47.0
ICD-10 Finland
Disorders of optic nerve, not elsewhere classified
40.8
6.8
8
*
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
2.4
6.8
46
202
U07
ICPC
Urine symptom/complaint other
3.0
6.6
29
101
SPAT1215
SPAT
Assessment of need for medical rehabilitation
3.8
6.6
20
55
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
3.2
6.4
25
81
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
2.4
6.4
43
188
SPAT1262
SPAT
Handing over of treatment supplies
2.2
6.4
58
289
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.5
6.3
42
182
H54.2
ICD-10 Finland
Moderate visual impairment, binocular
18.4
6.3
9
5
6BA02, ,
NOMESCO Finland
18.4
6.3
9
5
H04.10
ICD-10 Finland
Dry eye syndrome
2.2
6.3
54
263
L01BB04
ATC
cladribine; systemic
+∞
6.3
6
*
A03FA02
ATC
cisapride; oral, rectal
3.0
6.2
28
99
TKC20
NOMESCO Finland
Catheterisation of bladder
3.2
6.2
25
83
Z3231
NOMESCO Finland
Registered nurse
1.8
6.2
109
685
SPAT1226
SPAT
Implementation of occupational therapy rehabilitation plan
6.2
6.1
15
25
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
83
46
22.68
106.64
1.2
1.1
—
—
—
0
0
61
22
32.71
91.94
1.2
1.0
—
—
—
0
0
61
27
26.62
85.42
1.2
1.1
44.08
28.13
mg/l
2.69
56
22
125
235
7.37
68.48
4.4
2.6
9.87
10.03
g/l
0.19
119
216
52
37
16.07
58.12
1.2
1.1
—
—
—
0
0
50
39
14.57
52.99
1.2
1.1
—
—
—
0
0
47
35
15.14
51.09
1.1
1.1
—
—
—
0
0
41
24
18.98
50.39
1.1
1.1
0.99
1.09
u/l
0.36
12
15
62
79
9.15
46.93
1.3
1.3
8.67
7.60
e6/l
0.09
54
63
62
79
9.15
46.93
1.4
1.3
166.39
183.06
e6/l
0.04
54
66
60
78
8.92
44.63
1.2
1.2
3.61
3.61
mmol/l
0.01
54
72
288
1525
4.45
39.14
15.1
5.7
57.94
56.71
%
0.99
283
1441
61
99
7.12
37.24
1.8
1.6
44.10
0.01
iu/ml
—
8
17
300
1817
3.87
29.38
17.2
9.2
3.68
3.97
e9/l
2.11
286
1599
236
1283
3.14
26.62
2.8
2.2
91.30
74.14
nmol/l
10.81
226
1192
81
249
3.85
23.11
1.5
1.2
—
23.47
—
0
16
132
559
3.06
22.50
4.3
2.2
5.05
8.60
e6/l
1.33
116
493
32
19
18.23
20.86
5.6
2.7
—
—
—
0
0
161
812
2.68
19.22
5.9
2.5
10.82
138.67
e6/l
0.91
133
612
27
38
7.56
18.46
1.1
1.1
—
—
—
0
0
27
15
19.23
18.05
1.2
1.1
1569.81
1756.53
miu/ml
0.23
27
15
146
734
2.59
17.18
5.5
2.4
0.15
0.39
e6/l
1.90
120
539
90
361
2.94
16.35
2.0
2.0
28.33
29.63
s
1.65
85
355
187
1116
2.30
14.44
7.5
4.2
36.98
36.82
g/l
0.14
180
1058
18
8
23.50
13.01
3.8
1.4
—
—
—
0
0
89
423
2.43
11.21
4.7
2.2
0.47
0.96
e6/l
1.66
55
226
22
24
9.65
11.15
1.1
1.3
1.71
1.80
mmol/l
0.28
22
24
222
1537
2.04
10.57
7.8
4.2
0.00
0.00
estimate
0.50
46
296
49
178
3.01
10.42
2.8
1.6
—
—
—
0
0
21
25
8.81
10.18
7.0
2.8
46.69
46.76
%
0.00
13
12
220
1539
1.99
9.94
6.2
3.0
0.04
0.00
estimate
0.44
46
314
221
1559
1.97
9.63
6.3
3.1
0.00
0.00
estimate
-0.00
45
285
80
395
2.29
9.11
5.1
2.3
5.92
3.68
e6/l
0.36
48
200
227
1653
1.90
8.60
5.5
4.0
6.48
6.45
mmol/l
0.09
213
1513
213
1524
1.88
8.48
8.0
5.6
10.22
10.09
umol/l
0.06
202
1450
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
15
16
9.70
7.85
1.3
1.3
—
—
—
0
0
292
2348
1.98
7.78
10.2
6.9
77.15
73.96
u/l
0.58
282
2220
12
8
15.42
7.76
1.0
1.3
—
—
—
0
0
12
8
15.42
7.76
1.0
1.1
—
—
—
0
0
158
1105
1.73
6.19
8.7
9.3
1.19
1.11
inr
0.67
47
356
10
8
12.79
6.11
1.0
1.5
—
—
—
0
0
285
2358
1.79
5.91
4.4
3.8
9.67
9.43
mm/h
0.13
274
2222
32
126
2.68
5.87
1.4
1.3
—
—
—
0
0
10
9
11.36
5.82
1.0
1.3
—
—
—
0
0
12
16
7.70
5.67
1.3
1.1
—
—
—
0
0
10
10
10.23
5.56
1.0
1.6
—
—
—
0
0
88
534
1.84
5.52
1.6
1.6
112500446.89
26115083.59
pmol/l
0.35
80
471
286
2392
1.74
5.44
6.0
2.8
48.05
38.26
u/l
1.21
278
2298
11
14
8.05
5.38
1.2
1.2
—
—
—
0
0
174
1291
1.63
5.21
8.3
6.0
1.22
1.22
mmol/l
0.07
146
1107
68
387
1.92
5.19
1.6
1.6
1197.75
1225.36
nmol/l
0.09
57
301
9
9
10.20
5.05
1.0
1.2
—
—
—
0
0
30
125
2.52
4.94
2.1
2.2
—
—
—
0
0
68
394
1.88
4.91
1.9
1.8
—
—
—
0
0
8
7
11.63
4.80
3.0
3.3
—
—
—
0
0
161
1223
1.54
4.10
7.1
3.1
—
—
—
0
0
86
564
1.67
4.04
1.6
1.4
22.37
21.38
nmol/l
0.28
77
495
74
468
1.72
3.97
3.2
3.1
186.80
183.44
ng/l
0.01
31
284
44
237
1.97
3.94
2.6
2.2
400.75
3951.70
u/l
—
10
101
34
169
2.11
3.78
1.2
1.3
146.45
249.71
miu/ml
1.57
11
88
6
5
12.16
3.77
1.0
1.0
—
—
—
0
0
6
5
12.16
3.77
1.0
1.0
—
—
—
0
0
144
1088
1.51
3.67
6.8
3.0
26.93
30.21
u/l
1.50
138
1035
113
814
1.55
3.57
8.8
3.3
0.00
0.01
estimate
0.80
45
292
52
307
1.80
3.53
3.6
3.6
32.04
31.92
%
0.03
45
218
8
13
6.26
3.51
1.0
1.0
—
—
—
0
0
96
670
1.58
3.48
7.1
3.3
1.01
1.02
kg/l
0.60
12
80
356
3294
1.98
3.47
17.8
10.8
18.27
19.55
mg/l
0.29
276
2537
16
59
2.79
3.36
3.8
3.7
3.59
4.38
e9/l
0.93
16
59
148
1146
1.47
3.27
7.4
5.2
1.21
1.22
mmol/l
0.36
137
1063
129
973
1.49
3.24
3.4
3.1
25.88
28.93
ng/l
0.11
73
519
23
104
2.29
3.22
1.6
1.7
—
—
—
0
0
16
61
2.69
3.17
3.8
3.9
59.13
56.48
%
0.37
16
61
10
25
4.08
3.10
1.1
1.6
—
—
—
0
0
44
257
1.80
3.10
2.0
1.6
—
—
—
0
0
23
106
2.24
3.09
1.3
1.1
—
—
—
0
0
347
3208
1.77
3.06
17.5
11.0
3.93
3.93
mmol/l
0.08
341
3121
5
5
10.11
2.98
1.0
1.0
—
—
—
0
0
18
76
2.43
2.94
1.4
2.6
—
—
—
0
0
10
27
3.77
2.90
1.0
1.3
—
—
—
0
0
128
990
1.44
2.76
2.2
1.8
99.79
98.98
pmol/l
0.07
66
519
94
690
1.48
2.65
2.5
2.0
3.22
2.87
mg/l
0.63
88
599
23
116
2.04
2.51
1.6
1.6
—
—
—
0
0
7
16
4.43
2.48
1.1
1.3
—
—
—
0
0
298
3213
0.69
2.40
3.9
3.7
1.49
1.50
mmol/l
0.09
276
3040
42
263
1.67
2.36
2.1
1.7
—
—
—
0
0
24
127
1.95
2.31
2.8
1.6
0.22
0.23
g/l
0.46
24
122
40
251
1.66
2.23
2.9
4.2
218.70
233.75
u/l
0.59
40
244
52
352
1.55
2.14
6.7
2.5
4.61
6.78
umol/l
1.07
43
305
24
131
1.89
2.13
5.9
2.5
0.04
0.11
e6/l
1.34
24
126
305
3260
0.70
2.12
4.1
4.0
2.87
2.90
mmol/l
0.20
283
3079
5
10
5.05
2.07
1.0
1.0
87.60
95.80
%
—
5
10
301
3222
0.71
2.07
3.9
3.7
4.80
4.81
mmol/l
0.00
282
3067
9
32
2.85
2.01
1.6
1.1
—
—
—
0
0
9
32
2.85
2.01
1.6
1.1
—
—
—
0
0
24
134
1.84
2.00
2.9
1.6
1.07
1.18
g/l
1.17
24
127
188
1612
1.32
2.00
3.1
2.8
104.91
78.49
ug/l
1.05
179
1516
13
57
2.33
2.00
1.1
1.2
—
—
—
0
0
9
33
2.77
1.94
1.6
1.1
—
—
—
0
0
9
33
2.77
1.94
1.6
1.1
—
—
—
0
0
9
33
2.77
1.94
1.6
1.1
—
—
—
0
0
6
17
3.57
1.84
1.0
4.0
802.33
604.65
u/ml
—
6
17
113
909
1.34
1.84
2.9
3.0
2.35
2.35
mmol/l
0.05
102
827
289
3095
0.74
1.77
3.5
3.3
1.24
1.25
mmol/l
0.06
268
2913
20
110
1.86
1.76
1.8
2.0
—
—
—
0
0
9
36
2.53
1.75
1.3
1.3
—
—
—
0
0
113
926
1.31
1.60
2.7
2.3
53.54
62.32
u/l
0.88
107
871
29
184
1.62
1.59
2.2
1.5
—
—
—
0
0
27
413
0.63
1.54
1.8
1.6
—
—
—
0
0
6
21
2.89
1.51
4.2
1.3
—
—
—
0
0
14
72
1.98
1.50
2.5
1.5
—
—
—
0
0
19
109
1.78
1.49
1.2
1.3
—
—
—
0
0
34
230
1.52
1.45
3.1
3.5
4.51
4.63
pmol/l
0.39
27
205
10
47
2.16
1.35
2.8
3.9
—
5348.00
—
0
5
7
149
0.46
1.34
1.6
1.5
—
—
—
0
0
55
416
1.38
1.33
2.6
1.8
—
—
—
0
0
322
3049
1.33
1.31
5.6
4.7
1.71
1.77
mu/l
0.61
308
2873
11
55
2.03
1.28
2.5
4.1
—
1.17
—
0
6
45
333
1.40
1.24
3.3
2.2
20.80
24.22
%
0.84
35
286
13
71
1.86
1.21
1.0
1.3
—
1.23
—
0
6
279
2605
1.25
1.20
4.5
4.1
14.53
14.35
pmol/l
0.61
259
2457
8
39
2.07
1.16
1.8
1.5
—
—
—
0
0
7
30
2.36
1.13
1.3
1.5
—
—
—
0
0
11
194
0.55
1.12
1.2
1.4
—
—
—
0
0
11
194
0.55
1.12
1.2
1.4
—
—
—
0
0
11
194
0.55
1.12
1.2
1.4
—
—
—
0
0
11
194
0.55
1.12
1.2
1.4
—
—
—
0
0
87
722
1.26
1.11
2.5
2.5
301.90
7556.44
umol/l
3.61
82
652
33
237
1.43
1.09
3.5
2.3
0.23
0.23
g/l
0.19
33
225
7
32
2.21
1.08
2.1
1.8
—
—
—
0
0
22
322
0.66
1.06
1.4
1.5
—
—
—
0
0
15
90
1.69
1.05
2.0
2.3
1.37
1.34
g/l
0.07
15
81
5
106
0.46
1.02
1.2
1.5
—
—
—
0
0
11
61
1.83
0.99
2.0
2.1
—
—
—
0
0
42
321
1.35
0.98
2.7
1.7
—
—
—
0
0
9
50
1.82
0.97
4.4
2.9
26.91
24.18
mmol/l
—
9
50
0
31
0.00
0.97
0.0
1.5
—
—
—
0
0
81
678
1.25
0.96
5.5
3.7
9.47
10.34
mg/mmol
0.06
49
424
319
3050
1.26
0.96
15.3
9.5
94.23
90.34
ml/min/173m2
2.67
273
2490
47
368
1.32
0.94
3.3
3.9
20.36
22.43
%
0.28
19
137
6
27
2.24
0.94
5.2
1.6
1.19
1.43
promille
—
6
21
9
52
1.75
0.93
1.3
1.4
—
—
—
0
0
9
52
1.75
0.93
1.3
1.4
—
—
—
0
0
35
267
1.34
0.84
7.9
6.4
105.31
104.15
mmol/l
1.01
35
267
26
189
1.40
0.83
11.2
3.1
1.97
1.86
mmol/l
0.06
19
155
11
175
0.62
0.80
2.5
2.0
—
—
—
0
0
0
25
0.00
0.79
0.0
2.6
—
—
—
0
0
35
271
1.32
0.78
4.0
2.1
32.54
33.42
u/l
0.06
28
238
5
25
2.01
0.73
1.0
1.1
—
—
—
0
0
78
671
1.20
0.73
1.3
1.3
13.07
30.26
iu/ml
3.24
21
225
5
26
1.93
0.71
1.6
2.0
—
—
—
0
0
31
240
1.32
0.70
6.7
7.2
1.25
1.15
mmol/l
0.07
21
188
64
543
1.21
0.69
2.7
3.1
956.27
675.50
ng/l
0.22
57
445
10
61
1.66
0.69
2.6
1.2
—
—
—
0
0
7
42
1.68
0.68
1.1
1.1
—
—
—
0
0
83
726
1.18
0.65
1.8
1.8
0.59
0.80
mg/l
1.46
58
548
5
29
1.73
0.64
1.4
1.2
48.60
60.61
u/l
—
5
29
11
71
1.57
0.62
1.2
1.3
—
—
—
0
0
5
30
1.68
0.61
1.6
1.1
—
1.07
—
0
12
0
20
0.00
0.60
0.0
1.0
—
—
—
0
0
23
175
1.33
0.59
6.7
3.3
89.24
70.73
ng/l
0.38
23
161
0
23
0.00
0.58
0.0
1.0
—
—
—
0
0
0
23
0.00
0.58
0.0
1.5
—
—
—
0
0
8
125
0.63
0.55
1.5
1.6
—
—
—
0
0
11
74
1.50
0.54
1.1
1.1
—
10.36
—
0
7
376
3711
1.43
0.53
30.8
16.1
40.67
40.47
%
0.31
354
3536
13
180
0.71
0.52
1.9
2.1
4.68
2.43
mg/l
—
8
124
157
1464
1.12
0.50
2.9
2.4
—
—
—
0
0
71
798
0.87
0.49
1.5
1.6
1.39
1.40
mmol/l
0.04
61
701
15
200
0.74
0.49
1.3
1.5
—
—
—
0
0
7
47
1.50
0.48
1.9
2.2
—
—
—
0
0
17
130
1.32
0.44
2.2
1.8
—
—
—
0
0
14
104
1.36
0.43
7.3
2.3
0.53
0.66
%
1.36
14
104
5
32
1.57
0.42
1.0
1.1
—
—
—
0
0
8
58
1.39
0.41
1.6
1.8
—
—
—
0
0
5
33
1.52
0.41
1.4
1.2
—
—
—
0
0
73
658
1.13
0.41
1.4
1.3
4.32
10.73
u/ml
0.98
26
274
16
204
0.78
0.40
1.6
1.5
287.69
311.80
mu/l
0.18
16
183
8
61
1.32
0.39
1.9
1.9
—
—
—
0
0
77
698
1.13
0.39
2.7
1.9
—
—
—
0
0
9
66
1.37
0.38
1.0
1.1
—
—
—
0
0
30
253
1.20
0.38
3.2
3.0
—
—
—
0
0
91
836
1.12
0.38
1.3
1.2
0.64
1.94
u/ml
1.70
21
249
6
43
1.40
0.35
1.3
1.3
—
—
—
0
0
33
285
1.17
0.33
2.3
2.7
0.71
0.72
ug/l
0.01
21
157
75
687
1.11
0.33
1.9
2.1
—
—
—
0
0
93
863
1.10
0.32
1.7
1.6
—
—
—
0
0
7
53
1.33
0.31
1.0
1.5
—
—
—
0
0
7
57
1.23
0.29
1.4
1.6
—
—
—
0
0
7
57
1.23
0.29
1.0
1.5
—
—
—
0
0
7
57
1.23
0.29
1.4
1.6
—
—
—
0
0
8
64
1.26
0.27
1.6
1.4
—
—
—
0
0
8
67
1.20
0.26
1.1
1.1
—
—
—
0
0
26
227
1.16
0.24
1.9
2.1
34.12
42.69
u/ml
0.16
26
215
34
304
1.13
0.23
1.4
1.2
210.61
177.56
iu/ml
0.11
14
131
5
38
1.32
0.23
1.6
1.5
—
—
—
0
0
5
38
1.32
0.23
1.6
1.5
—
—
—
0
0
5
40
1.25
0.22
1.0
1.5
—
—
—
0
0
5
41
1.22
0.22
1.0
1.5
—
—
—
0
0
5
42
1.19
0.21
1.0
1.5
—
—
—
0
0
5
42
1.19
0.21
1.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.4
—
—
—
0
0
8
101
0.79
0.21
1.3
1.4
—
—
—
0
0
0
12
0.00
0.21
0.0
4.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
4.3
—
—
—
0
0
5
43
1.16
0.21
1.0
1.4
—
—
—
0
0
5
43
1.16
0.21
1.0
1.4
—
—
—
0
0
5
43
1.16
0.21
1.0
1.4
—
—
—
0
0
5
43
1.16
0.21
1.0
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
2.9
—
112.85
—
0
13
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
23
204
1.14
0.18
6.9
6.2
1.16
1.21
mmol/l
0.15
23
199
22
195
1.14
0.18
1.5
1.5
—
—
—
0
0
20
226
0.88
0.17
1.2
1.5
—
—
—
0
0
19
215
0.88
0.17
1.0
1.0
—
—
—
0
0
87
830
1.06
0.16
1.6
1.5
—
—
—
0
0
33
302
1.10
0.16
9.1
5.7
—
—
—
0
0
20
178
1.13
0.15
1.3
1.6
—
—
—
0
0
9
79
1.14
0.15
1.9
1.5
—
—
—
0
0
277
2805
0.96
0.12
5.1
4.5
38.22
38.44
mmol/mol
0.13
266
2673
66
632
1.05
0.11
1.8
2.0
—
—
—
0
0
308
3050
1.05
0.11
4.0
3.6
5.77
5.72
mmol/l
0.25
289
2852
15
135
1.12
0.10
5.2
5.1
24.25
24.56
mmol/l
0.19
15
135
24
224
1.08
0.08
2.3
2.3
73.71
78.72
ml/min/173m2
—
7
94
7
66
1.06
0.08
1.4
1.2
—
—
—
0
0
24
225
1.07
0.07
1.7
1.4
—
—
—
0
0
7
84
0.83
0.07
1.0
1.2
—
—
—
0
0
13
118
1.11
0.07
1.0
1.1
—
5.52
—
0
21
9
105
0.85
0.06
1.6
1.2
—
—
—
0
0
9
105
0.85
0.06
1.6
1.2
—
—
—
0
0
17
158
1.08
0.06
1.6
1.4
—
—
—
0
0
266
2667
0.99
0.01
3.4
3.7
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
5
51
0.98
-0.00
1.2
1.1
—
—
—
0
0
6
66
0.91
-0.00
4.5
2.7
5.48
5.43
umol/l
—
6
49
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
9
92
0.98
-0.00
1.3
1.5
20.02
23.67
u/l
—
9
74
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
8
82
0.98
-0.00
1.4
1.5
—
—
—
0
0
7
71
0.99
-0.00
1.1
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
4.0
—
101.13
—
0
8
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint G6_DISSOTH and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_DISSOTH | 2.024 [1.58, 2.6] | < 0.001 |
| Birth year | 0.996 [0.99, 1.0] | 0.361 |
During the follow-up period (1.1.1998 — 31.12.2019), 114 out of 1346 females with G6_DISSOTH died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_DISSOTH | 2.036 [1.57, 2.63] | < 0.001 |
| Birth year | 0.988 [0.98, 1.0] | 0.018 |
During the follow-up period (1.1.1998 — 31.12.2019), 94 out of 622 males with G6_DISSOTH died.
Mortality risk
Mortality risk for people of age
years, who have G6_DISSOTH.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.179% | 0.402% |
| 5 | 1.097% | 2.427% |
| 10 | 3.192% | 6.325% |
| 15 | 6.203% | 11.838% |
| 20 | 10.507% | 19.86% |
Relationships between endpoints
↥Index endpoint: G6_DISSOTH – Other acute disseminated demyelination
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data